Schlagwörter

• Adolescent, Antineoplastic Agents/therapeutic use, Child, Child, Preschool, Drug Administration Schedule, Female, Fusion Proteins, bcr-abl/antagonists & inhibitors, Gene Expression, Germany, Humans, Imatinib Mesylate/therapeutic use, Infant, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Male, Protein Kinase Inhibitors/therapeutic use, RNA, Messenger/antagonists & inhibitors, Treatment Outcome